Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
New Hampshire Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Genentech
< Previous
1
2
3
Next >
Genentech’s Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials
October 10, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
October 04, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD
October 02, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition
September 06, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Alecensa Delivers Unprecedented Phase III Results for People With ALK-Positive Early-Stage Lung Cancer
September 01, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Provides Update on Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
August 23, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Clinical and Real-World Data for Genentech’s Vabysmo at ASRS Reveal Improved Outcomes for People With Two Leading Causes of Vision Loss
July 20, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis
July 13, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
June 30, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
June 15, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
June 09, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
May 17, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
May 09, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
April 25, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
April 24, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
April 19, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
April 16, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
April 13, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA)
March 20, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Advisory Committee Votes in Favor of the Clinical Benefit of Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
March 09, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
New Phase III Data Show Genentech’s Vabysmo Rapidly Improved Vision and Reduced Retinal Fluid in People With Retinal Vein Occlusion (RVO)
February 10, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Announces Positive Data From Global Phase III Program for Crovalimab in PNH, a Rare, Life-Threatening Blood Condition
February 07, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
January 19, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma
January 06, 2023
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular Lymphoma
December 22, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
December 21, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
December 12, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
December 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
December 11, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
November 14, 2022
From
Genentech
Via
Business Wire
Tickers
RHHBY
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.